JMP Securities analyst Joseph Osha maintained a Market Outperform rating on Heron Therapeutics and raised his price target on the shares to $38 from $33 after the company resubmitted its New Drug Application to the FDA for HTX-011, an investigational agent for the management of postoperative pain. Osha said he is "pleased" with management's timely resolution of the complete response letter issues concerning additional chemistry, manufacturing and controls as well as non-clinical information. The analyst added that he now anticipates a launch roughly 6-8 weeks following the late March PDUFA date.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Heron Therapeutics (HRTX),... To see the rest of the story go to thefly.com. See Story Here

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here